Healthtech Startups

Curis is a biopharmaceutical company focused on drug development and clinical advancement. The company's board includes experienced leaders in oncology, immunology, dermatology, and pharmaceutical development.

1 investor

Curiteva designs, manufactures, and commercializes spinal surgical instruments and implants, and is noted for 3D-printing commercially available PEEK implants for cervical, thoracolumbar, and sacroiliac spine applications. Its products serve spine surgeons and physicians treating spinal conditions.

1 investor

Curiva develops diaPatch, a non-invasive wearable diagnostic patch that samples interstitial fluid via microneedles and runs a molecular assay to support cervical cancer risk stratification and triage after an abnormal Pap smear. It targets cancer centers, hospitals, clinics, and physician offices to reduce reliance on invasive colposcopy and deliver same-visit results.

1 investor

Curovate offers digital physical therapy and rehabilitation guidance for people recovering from or considering knee replacement and other joint or orthopedic conditions. Its content and app support patients through recovery with exercise and recovery tracking.

1 investor

Current Clinic operates a network of healthcare centers specializing in the diagnosis and treatment of atrial fibrillation and other cardiac arrhythmias. The company delivers cardiology services outside traditional hospital settings to reduce costs and improve access to care.

1 investor

Provides medical waste disposal services and products, including containers for sharps, regulated medical waste, universal waste, and unused medications, plus mail-back kits. Serves healthcare facilities ranging from single-provider clinics to multi-site healthcare networks across the US.

1 investor

Curve Dental provides practice management and clinical software for dental practices, offering integrated charting, scheduling, insurance verification, patient billing, and ambient AI-powered documentation tools.

1 investor

Curvo provides supply spend management software that normalizes and analyzes healthcare supply data across vendors and products. The platform helps healthcare organizations benchmark pricing, identify purchasing variations, and make data-driven sourcing decisions to reduce costs.

1 investor

Cuspa develops a minimally invasive medical device using an artificial cusp that merges with the native aortic valve to treat aortic regurgitation, addressing a gap for patients with moderate to severe AR who lack repair options. The company operates in the medical device sector focused on structural heart and aortic valve disease treatment.

1 investor

Customy is an ISO 13485 certified medical software (SaMD) company that develops tools for processing CT/MRI medical images into 3D models, supporting 3D printing and preoperative virtual surgery planning. Its platform serves surgeons, radiologists, and biomedical engineers, and the company also designs patient-specific implants, surgical guides, and anatomical models for craniofacial reconstructions.

1 investor

Cutanos is a biotechnology company developing a Langerhans Cell Targeted Delivery System (LC-TDS) that uses a langerin-specific glycomimetic ligand to direct lipid nanoparticle and mRNA/protein formulations to specific skin-resident dendritic cells for vaccines and immunotherapies. The platform is administered via minimally invasive microneedles or microinjectors and targets next-generation vaccines, cancer immunotherapy, and autoimmune disease applications.

1 investor

Cuvris builds specialty-focused AI agents that automate healthcare practice operations, including referral triage, patient intake, qualification, scheduling, and clinical documentation. It serves care teams and medical practices to reduce administrative workload, improve chart accuracy, and lower claim denials.

1 investor

CV6 Therapeutics develops investigational cancer therapies designed for combination use with established standards of care, with a lead program (CV6-168) intended to enhance the activity of 5-fluorouracil and other thymidylate synthase-targeted therapies. The company is advancing CV6-168 through Phase 1a clinical development.

1 investor

CvergenX develops the precisionRT Dose (pRTD) platform, which uses gene-expression biomarkers (RSI) and the Genomic Adjusted Radiation Dose (GARD) metric to predict tumor radiosensitivity and personalize radiotherapy dosing. It provides predictive analytics for biologically guided radiation oncology, serving clinical and research use in cancer treatment.

1 investor

CVS Health is a health care company that connects people to care through insurance plans, retail and specialty pharmacies, prescription delivery, walk-in appointments, and a pharmacy benefit manager. It serves individuals and families in the United States, offering services to manage chronic conditions, mental and physical well-being, and access to affordable medications.

1 investor

CWS provides hygiene, protective workwear, cleanroom, fire protection, and healthcare products and services for businesses. The company operates across five business divisions focused on workplace safety, health, and sustainability solutions.

1 investor

Cyagen provides preclinical research services including cell and animal model development, viral packaging, and expert-led preclinical studies to support IND applications. It serves life science researchers and biopharmaceutical organizations in drug development.

1 investor

Cyberpsyc is a Canadian provider of online mental health support delivered through computerized cognitive behavioral therapy. Its interactive, self-directed programs address stress, anxiety and depression, with a focus on student users.

1 investor

Cyclarity Therapeutics develops engineered cyclodextrin drugs that target and remove toxic oxidized cholesterol (7-ketocholesterol) to treat atherosclerosis and other age-related diseases. Its lead candidate, UDP-003, is a preclinical/early clinical therapy aimed at cardiovascular disease, with additional pipeline programs for stroke recovery, Alzheimer's, and other conditions.

1 investor

Cyclops Medtech develops a portfolio of vestibular diagnostic and therapy products—including videonystagmography (VNG/VOG), video head impulse testing (vHIT), dynamic visual acuity, stabilometry platforms, VR-based vestibular rehabilitation, and a smart balance board—to diagnose and treat dizziness and balance disorders. Its tools serve clinicians across neurotology, neurology, physiotherapy, audiology, and ophthalmology.

1 investor

Cyclotek manufactures and distributes PET radiopharmaceuticals and radioactive medical devices for hospitals, research institutions, and clinical partners across Australia and New Zealand. The company provides GMP manufacturing, supply chain coordination, and translational support to enable molecular imaging diagnostics and therapy.

1 investor

Cycuria Therapeutics develops engineered biologics to treat blood cancers, targeting leukemic cells and their progenitor stem cells while sparing healthy blood formation, with an initial focus on Acute Myeloid Leukemia (AML). Its lead program is CUR-101, aimed at patients including older or unfit individuals who cannot tolerate intensive chemotherapy or stem cell transplants.

1 investor

CyDen develops clinically proven light-based hair and skin wellness devices, transforming professional aesthetic technologies into safe, effective at-home consumer products. The company serves consumers seeking at-home beauty treatments and wellness solutions.

1 investor

Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation. Made by CyDex Pharmaceuticals (a Ligand company), it is used in approved therapeutics including remdesivir and carfilzomib, and is also explored for consumer health, supplements, and personal care products.

1 investor